Russia mandates HPV DNA testing to combat cervical cancer risks

Russia has expanded its mandatory health checks for women by including HPV DNA testing. The new rule applies to all women aged 21 to 49 under the country’s compulsory health insurance system. This change aims to detect early signs of cervical cancer risk through routine screenings.

HPV, or human papillomavirus, is a widespread group of viruses spread through sexual contact and sometimes household exposure. While 50 to 80 percent of people globally carry HPV, only 5 to 10 percent ever show symptoms. Certain high-risk strains, however, are strongly linked to cervical cancer.

Under the updated programme, a positive HPV DNA test leads to a second stage of screening. This involves liquid-based cytology, also known as oncocytology, for further assessment. The move follows growing recognition of HPV’s role in cancer development. Looking ahead, Russia may introduce the HPV vaccine into its National Immunization Schedule by 2027. If approved, the vaccine could be offered free of charge to eligible individuals across the country.

The inclusion of HPV testing in routine checkups marks a shift in Russia’s preventive healthcare approach. Early detection through DNA screening could reduce cervical cancer cases over time. Meanwhile, plans for free vaccination suggest a broader strategy to lower HPV-related health risks in the coming years.